International journal of science and healthcare research, 2023 The following article elucidates the role of oral therapy for uterine fibroids in increasing the quality of life and a better treatment option as compared to the conventional methods, which are operative and may result in infertility.
Aparna Arora +2 more
semanticscholar +2 more sources
Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed‐Dose Combination Product: Phase 1 Results in Healthy Pre‐ and Postmenopausal Women [PDF]
Clinical pharmacology in drug developmentFixed‐dose combination (FDC) therapies can enhance patient convenience and adherence to prescribed treatment regimens. Elagolix is a novel oral gonadotropin‐releasing hormone receptor antagonist approved for management of moderate to severe pain ...
Mong-Jen Chen +5 more
semanticscholar +2 more sources
Suppression of an accessory and cavitated uterine mass with norethindrone: a case report [PDF]
F&S ReportsObjective: To describe conservative management for accessory and cavitated uterine mass (ACUM) with norethindrone acetate. The patient gave signed written, informed consent authorizing publication.
Hope Knochenhauer, M.D. +2 more
doaj +2 more sources
A Matched Case-Control Study Examining the Association Between Exposure to Depot Medroxyprogesterone Acetate and Cerebral Meningioma Using an Active Comparator [PDF]
Current OncologyThe recent literature has reported an increased association between the use of depot medroxyprogesterone acetate (dMPA) and cerebral meningioma (CM). Prior studies have been limited in generalizability and did not use an active comparator as a control ...
Russell Griffin, Rebecca Arend
doaj +2 more sources
Bone mineral density with elagolix plus add-back therapy in women with heavy menstrual bleeding and uterine fibroids: open-label and post-treatment results of a 60-month phase 3 trialAJOG Global Reports at a Glance [PDF]
AJOG Global ReportsBackground: The gonadotropin-releasing hormone antagonist elagolix (ELA) plus hormonal add-back (+AB) therapy reduces menstrual blood loss in women with heavy menstrual bleeding (HMB) associated and uterine fibroids.
Vicki L. Schnell, MD +6 more
doaj +2 more sources
Relugolix, Estradiol, and Norethindrone Acetate (Myfembree)
Canadian Journal of Health TechnologiesReimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
CDA-AMC
semanticscholar +3 more sources
Safety and efficacy of relugolix combination therapy in symptomatic uterine fibroids [PDF]
Facts, Views & Vision in ObGynBackground: Relugolix-combination therapy (CT) (oestradiol 1 mg and norethindrone acetate 0.5 mg) is a new gonadotropin-releasing hormone antagonist licensed to treat heavy menstrual bleeding (HMB) associated with uterine fibroids; but little real-world ...
Maria Chiara De Angelis +7 more
doaj +2 more sources
Progestin Pollution in Surface Waters of a Major Southwestern European Estuary: The Douro River Estuary (Iberian Peninsula) [PDF]
ToxicsThe concentrations and spreading of eight synthetic and two natural progestins (PGs) were investigated in surface waters from ten sites at the Douro River Estuary.
Frederico Silva +3 more
doaj +2 more sources
Relugolix, Estradiol, and Norethindrone Acetate.
American Journal of Health-System Pharmacy, 2021 semanticscholar +3 more sources
COMPARING THE CARDIOVASCULAR RISK OF NORETHINDRONE ACETATE- AND LEVONORGESTREL-CONTAINING ORAL CONTRACEPTIVES: IS THERE A DIFFERENCE? [PDF]
, 2020 C. Barnett +3 more
semanticscholar +2 more sources